公开(公告)号：US11046774B2

公开(公告)日：2021-06-29

申请号：US16285118

申请日：2019-02-25

Applicant: AMGEN INC.

Inventor： Junming Yie ,  Donghui Shi ,  David J. Lloyd ,  Jinghong Wang ,  Glenn N. Sivits, Jr. ,  Murielle M. Veniant-Ellison ,  Renee Komorowski ,  Neeraj Agrawal ,  Darren L. Bates ,  Brandon C. P. Clavette ,  Ian N. Foltz ,  Shu-yin Ho ,  Christopher Murawsky ,  Xiaoshan Min ,  Zhulun Wang

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/17 ,  A61K38/26 ,  A61K9/00 ,  A61K39/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US10894814B2

公开(公告)日：2021-01-19

申请号：US15826442

申请日：2017-11-29

Applicant: Amgen Inc.

Inventor： Yumei Xiong ,  Yi Zhang ,  Jackie Z. Sheng ,  Agnes Eva Hamburger ,  Murielle M. Veniant-Ellison ,  Grant Shimamoto ,  Xiaoshan Min ,  Zhulun Wang ,  Jie Tang ,  Gunasekaran Kannan ,  Marissa Mock ,  Kenneth William Walker

IPC: C07K14/475

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20190276546A1

公开(公告)日：2019-09-12

申请号：US16285118

申请日：2019-02-25

Applicant: AMGEN INC.

Inventor： Junming Yie ,  Donghui Shi ,  David J. Lloyd ,  Jinghong Wang ,  Glenn N. Sivits, JR. ,  Murielle M. Veniant-Ellison ,  Renee Komorowski ,  Neeraj Agrawal ,  Darren L. Bates ,  Brandon C. P. Clavette ,  Ian N. Foltz ,  Shu-yin Ho ,  Christopher Murawsky ,  Xiaoshan Min ,  Zhulun Wang

IPC: C07K16/28 ,  A61K9/00 ,  A61K38/26 ,  A61K39/395 ,  A61K38/17

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US10294303B2

公开(公告)日：2019-05-21

申请号：US15387542

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： Junming Yie ,  Donghui Shi ,  David J. Lloyd ,  Jinghong Wang ,  Glenn N. Sivits, Jr. ,  Murielle M. Veniant-Ellison ,  Renee Komorowski ,  Neeraj Agrawal ,  Darren L. Bates ,  Brandon C. P. Clavette ,  Ian N. Foltz ,  Shu-yin Ho ,  Christopher Murawsky ,  Xiaoshan Min ,  Zhulun Wang

IPC: A61K39/39 ,  C07K16/28 ,  A61K38/26 ,  A61K39/395 ,  A61K9/00 ,  A61K38/17 ,  A61K39/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20190046611A1

公开(公告)日：2019-02-14

申请号：US16054035

申请日：2018-08-03

Applicant: AMGEN INC.

Inventor： Khaled M.K.Z. Ali ,  Neeraj Jagdish Agrawal ,  Gunasekaran Kannan ,  Ian Foltz ,  Zhulun Wang ,  Darren Bates ,  Marissa Mock ,  Shunsuke Takenaka

IPC: A61K38/20 ,  A61P35/00 ,  C12N15/63 ,  C07K16/28

Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.